FATE Fate Therapeutics, Inc.

NASDAQ
$1.94

Fate Therapeutics, Inc. (FATE) is expected to report earnings on February 4, 2027, before the market open. The consensus earnings estimate is a loss of $0.29 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.5% since its last earnings release on November 5, 2026.

Fate Therapeutics Beat Consensus Estimates
Thursday, November 5, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($0.29)
Rev est $1.5M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.84

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Fate Therapeutics, Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells. It has built two platforms: HSC modulation platform and Satellite Cell modulation platform.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.